BetaGlue Therapeutics is a company dedicated to pioneering highly-innovative precision radiotherapy products. Their mission is to provide life-changing, personalized treatment options for solid tumor cancer patients that are easy to use, cost-effective, and resource-efficient for healthcare providers and payers.

BetaGlue Therapeutics

BetaGlue Therapeutics is a clinical stage oncology company that has developed  an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose.

BetaGlue is pleased to announce a further €8m financing from existing and new investors. The round was led by Neva SGR and Liftt SpA. Combined with the recently announced €10m EIC Accelerator award, the €18m will be used to accelerate the development of YntraDose across multiple indications in parallel.
See full press release here: https://lnkd.in/e9xgcQag
Mario Costantini Liliana Nordbakk Francesco Fontana Francesca Mongardi Luca Petroni Giovanni Cerutti Colin Story Diana Saraceni Claudio GIULIANO Michel Therin Mike Cogswell Michael Maszy Salvatore Calabrese Gianluca De Danieli MD PhD MSc Pietro Bubba Bello Betty Polikar Gaia Bisaccioni Pieter Janssen
#NevaSGR #Liftt #BetaGlue #radiotherapy #oncology #innovation

BetaGlue would like to recognise Lira for the expert support and guidance they offered us in the EIC Accelerator process. Our thanks and gratitude to team Lira ! Lorenzo Stramucci Emmanuele Angione Betty Polikar Pietro Bubba Bello Gianluca De Danieli MD PhD MSc Gaia Bisaccioni
#betaglue #lira-ltd #oncology #radiotherapy #innovation #eicaccelerator

BetaGlue further strengthens its board through the appointment of Mr Mike Cogswell as Chairman and Mr Mike Maszy as Non-Executive Director. See the full press release here: https://lnkd.in/e9xgcQag 
Colin Story Salvatore Calabrese Pietro Bubba Bello Gianluca De Danieli MD PhD MSc Betty Polikar Gaia Bisaccioni Pieter Janssen Mike Cogswell Michael Maszy Liliana Nordbakk Francesco Fontana Francesca Mongardi Michel Therin Claudio GIULIANO Giovanni Cerutti Diana Saraceni Panakes Partners Innogest Capital LIFTT 
#betaglue #innovation #yntradose #radiotherapy #oncology

BetaGlue is rebranded as BetaGlue Therapeutics and its novel radiotherapy platform named YntraDose. Check out our new website at www.betaglue.com featuring the technology, clinical data, the pipeline, what the clinicians say and much much more. A big thank you to the team at Cohesion Labs for helping us make this happen! Colin Story Pietro Bubba Bello Gianluca De Danieli MD PhD MSc Betty Polikar Gaia Bisaccioni Pieter Janssen Salvatore Calabrese Panakes Partners Innogest Capital LIFTT Craig Stockwell Kat Arney Cohesion Labs
#betaglue #yntradose #radiotherapy #oncology #innovation

BetaGlue's CEO, Colin Story is welcomed as an advisory board member to the UK Innovation & Science Seed Fund.
#betaglue

BetaGlue announces it has won a prestigious €10m EIC Accelerator Award. Of 1,083 applicants BetaGlue was one of only 42 (~4%) successful companies to secure funding. This major achievement recognises BetaGlue's clinical and commercial potential in addition to the calibre of the executive team. Colin Story Gianluca De Danieli MD PhD MSc Pietro Bubba Bello Betty Polikar Gaia Bisaccioni Salvatore Calabrese Giovanni Parisio Riccardo Palmisano Giovanni Cerutti Luca Melindo Claudio GIULIANO Michel Therin Francesca Mongardi Francesco Fontana Giacomo Piccinini
#betaglue #radiotherapy #oncology #innovation #liftt #panakes #eicaccelerator #lira.ltd #neva #innogest

BETA

COM:BETAGLUE

BetaGlue Therapeutics

Financials Not Available